Cell type-resolved transcriptomic map of skeletal muscle in women with polycystic ovary syndrome

This study establishes a cell-type-resolved transcriptomic atlas of skeletal muscle in women with PCOS, revealing that hyperinsulinemia and hyperandrogenism drive pro-fibrotic remodeling through fibro-adipogenic progenitor reprogramming and altered myofiber crosstalk, which can be partially reversed by metformin.

The Gist

The Big Picture: A City in Trouble

Imagine the human body as a bustling city. Skeletal muscle is the city's main power plant and factory district, responsible for burning fuel (glucose) to keep everything running.

In women with Polycystic Ovary Syndrome (PCOS), this power plant is malfunctioning. It's not just that the factory is slow; the whole neighborhood is changing. The roads are getting clogged with traffic (insulin resistance), the buildings are getting stiff and scarred (fibrosis), and the workers are confused about how to process energy.

For a long time, scientists looked at the muscle as a single, giant block of concrete. They knew it was broken, but they didn't know which specific workers were causing the problem or how to fix them.

This study is like sending a drone fleet with high-definition cameras into that muscle city. Instead of looking at the whole neighborhood, they zoomed in to see every single cell, every worker, and every conversation happening between them.

---

The Cast of Characters (The Cells)

The researchers identified four main groups of "workers" in the muscle city:

1. The Muscle Fibers (The Workers): These are the actual engines that contract and move your body. They come in different types: some are marathon runners (slow-twitch), and some are sprinters (fast-twitch).
2. The FAPs (The Construction Crew): These are "Fibro-adipogenic progenitors." Think of them as the city's maintenance crew. Their job is to repair damage and build new structures. In a healthy city, they fix things. In PCOS, they get confused and start building too many walls (scar tissue/fibrosis) instead of fixing the roads.
3. The Satellite Cells (The Apprentices): These are stem cells waiting to become new muscle fibers when needed.
4. The Immune & Blood Cells (The Police and Delivery Trucks): They manage inflammation and transport nutrients.

---

What Went Wrong in the PCOS City?

1. The Workers Are Stressed Out

The study found that the Muscle Fibers in women with PCOS are struggling to switch fuels. Normally, a muscle can switch between burning sugar (glucose) and fat easily. In PCOS, the "sprinters" (fast-twitch fibers) are stuck trying to burn fat but can't process sugar well. They are like a car engine that is sputtering because the fuel mix is wrong. This leads to a buildup of toxic waste (oxidative stress).

2. The Construction Crew Has Gone Rogue

This was the biggest discovery. The FAPs (Construction Crew) have changed their personality.

• Normal FAPs: "Let's repair this small tear and move on."
• PCOS FAPs: "Let's build a massive concrete wall here!"
  They have switched to a "pro-fibrotic" mode. They are flooding the muscle with collagen (scar tissue), making the muscle stiff and less flexible. It's like the maintenance crew decided to pave over the entire factory floor with concrete, making it hard for the workers to move.

3. The Hormone Chaos

The city is being run by two chaotic mayors: High Insulin and High Androgens (male hormones).

• The study found that these "mayors" are directly shouting orders to the Construction Crew (FAPs), telling them to build more scar tissue.
• They are also whispering confusing instructions to the Muscle Workers, telling them to stop burning sugar efficiently.

---

The Hero: Metformin (The City Planner)

Doctors often prescribe Metformin to women with PCOS to lower blood sugar. But how does it work at the cellular level? This study finally answered that.

Think of Metformin as a new, very smart City Planner arriving to fix the chaos.

• Did it fix the Workers? Surprisingly, no. The Muscle Fibers (the workers) were still struggling with their fuel mix even after Metformin treatment. The "metabolic memory" of the disease was too strong for the drug to fix the workers directly.
• Did it fix the Construction Crew? YES! This is the breakthrough. Metformin went straight to the FAPs and told them to stop building those massive concrete walls. It calmed them down, reversed the scar-tissue signals, and helped them return to normal repair work.

The Analogy: Imagine a factory where the machines (muscle) are broken, and the repair crew (FAPs) is making things worse by building walls. Metformin couldn't fix the broken machines directly, but it successfully told the repair crew to stop building walls and start fixing the machines properly.

---

The "In Vitro" Experiment: The Memory Effect

The researchers took muscle cells from women with PCOS and grew them in a lab dish, away from the chaotic body environment.

• The Result: Even without the high hormones of the body, the muscle cells still acted "sick" (they had low energy). This proves that the disease has "imprinted" a memory on the cells. The cells remember being sick even when they are in a healthy environment.
• However: When they added insulin to the dish, the PCOS cells actually responded just fine! This suggests that while the cells have a "memory" of being sick, they haven't lost the ability to listen to commands entirely. They just need the right environment to function.

---

The Takeaway: Why This Matters

1. It's Not Just One Thing: PCOS muscle problems aren't just about "bad muscles." It's a communication breakdown between the muscle fibers and the construction crew (FAPs).
2. Metformin Has a Specific Job: We used to think Metformin just lowered blood sugar. Now we know it specifically targets the "Construction Crew" to stop them from scarring the muscle. This explains why it helps, even if it doesn't fix every single cell type.
3. New Targets for Medicine: Since Metformin doesn't fix the muscle fibers directly, scientists now know they need to find new drugs that can specifically help the muscle fibers switch fuels better, while Metformin handles the scarring.

In short: This study mapped the cellular city of PCOS, found out that the "Construction Crew" is the main culprit behind the stiffness and scarring, and discovered that Metformin is a great boss for that specific crew, even if it needs help fixing the rest of the city.

Technical Summary

1. Problem Statement

Polycystic Ovary Syndrome (PCOS) affects ~15% of women and is strongly linked to metabolic complications, including insulin resistance, type 2 diabetes, and cardiovascular disease. While skeletal muscle insulin resistance is a hallmark of PCOS, the specific cellular origins and molecular mechanisms driving this pathology remain unclear. Previous bulk tissue studies have masked cell-type-specific heterogeneity. Furthermore, the mechanism of action of metformin, a first-line treatment for PCOS-related insulin resistance, is poorly understood at the single-cell level within human skeletal muscle. There is a critical need to map the cellular landscape of PCOS muscle to identify novel therapeutic targets beyond systemic insulin sensitization.

2. Methodology

The study employed a multi-modal approach combining in vivo human biopsies with in vitro validation:

• Cohort and Sampling:
  • Participants: 19 women with PCOS (hyperinsulinemic and hyperandrogenic) and 10 age-, weight-, and BMI-matched controls.
  • Intervention: A subset of 5 PCOS patients underwent a 16-week metformin intervention (1500 mg/day).
  • Tissue: Vastus lateralis muscle biopsies were collected at baseline and post-intervention.
• Single-Nuclei RNA Sequencing (snRNA-seq):
  • Scale: Generated an atlas of 72,247 nuclei from 19 biopsies.
  • Protocol: 10X Genomics Chromium Next GEM Single Cell 3' v3.1.
  • Analysis: Data processing included ambient RNA removal (DecontX), integration (Seurat), and clustering. Cell types were annotated based on established markers.
  • Subclustering: Major cell populations (Muscle fibers, FAPs, Satellite cells, Immune, Endothelial, Perivascular) were further subclustered to identify specific subpopulations.
• Computational Analyses:
  • Differential Expression: MAST method for identifying DEGs.
  • Functional Enrichment: Gene Ontology (GO) and pathway analysis.
  • Metabolic Inference: scCellFie was used to infer metabolic task activity based on gene-protein-reaction rules.
  • Cell-Cell Communication: CellChat was utilized to map ligand-receptor interactions and signaling pathways between cell types.
  • Genetic Prioritization: CELLEX/CELLECT linked GWAS data to specific cell types.
• In Vitro Validation:
  • Satellite Cell Culture: Isolated satellite cells from PCOS and control biopsies were differentiated into myotubes.
  • Assays: Prime-seq (transcriptomics), Seahorse XFe96 (mitochondrial respiration/OCR), Glucose Uptake-Glo assay, and Immunofluorescence.
• Spatial Validation:
  • Multiplex Tissue Profiling: Iterative antibody-based imaging (Opal) on FFPE sections to validate the spatial localization of key DEGs (e.g., COL4A2, ELN, LAMB1) relative to muscle fiber types.

3. Key Contributions

• First Single-Nuclei Atlas: This is the first comprehensive transcriptional and spatial atlas of human skeletal muscle in women with PCOS.
• Cell-Type Specificity: It moves beyond bulk tissue analysis to reveal distinct molecular signatures in specific cell types, particularly Fibro-Adipogenic Progenitors (FAPs) and specific muscle fiber subtypes.
• Metformin Mechanism: It provides the first single-cell resolution map of metformin's effects in human skeletal muscle, revealing that the drug acts selectively on specific stromal populations rather than uniformly across all muscle cells.
• FAP-Driven Fibrosis: It identifies FAPs as the primary drivers of pro-fibrotic remodeling in PCOS, linking systemic hormonal imbalances to local tissue pathology.

4. Key Results

A. Muscle Fiber Subtypes: Metabolic Inflexibility

• Subpopulations: Identified four fiber types: MF-I (Type I), MF-IIa, MF-IIx, and Hybrid I-II.
• Dysregulation: PCOS fibers showed fiber-type-specific metabolic impairment.
  • MF-IIa and MF-IIx: Exhibited downregulated glucose handling (glycolysis/glycogen) and upregulated fatty acid oxidation and ROS detoxification pathways, indicating a shift toward lipid utilization and oxidative stress.
  • Hybrid I-II: Showed hypoxia-dependent reprogramming (upregulated COX7A1, COX6A2) and increased oxidative stress.
• Metformin Effect: Metformin showed limited reversal of metabolic dysfunction in muscle fibers. It reversed specific genes (e.g., PRKAG2, ANKRD2) in MF-IIx but did not normalize broader metabolic pathways or mitochondrial function.

B. Fibro-Adipogenic Progenitors (FAPs): The Pro-Fibrotic Hub

• Subpopulations: Identified three FAP clusters: GPC3+, MME+, and FBN1+.
• Pathology:
  • GPC3+ and MME+ FAPs displayed a strong pro-fibrotic phenotype in PCOS, characterized by upregulated TGF-β signaling, ECM organization, and collagen production (COL14A1, ELN).
  • Metabolic Reprogramming: These FAPs showed a distinct metabolic shift toward glutamine metabolism and ECM biosynthesis (upregulated proline, ornithine, and glycosylation tasks), fueling collagen production.
• Metformin Effect: Metformin selectively reversed the pro-fibrotic transcriptional signatures in GPC3+ and MME+ FAPs, normalizing ECM organization and TGF-β pathways. However, it did not fully restore metabolic tasks like oxidative phosphorylation in these cells.

C. Satellite Cells and Immune Cells

• Satellite Cells: PAX7+ and ENO3+ subpopulations showed dysregulation in growth signaling and muscle system processes. Metformin partially rescued some pathways but exacerbated contractile gene disturbances in some contexts.
• Immune/Endothelial: Immune cell proportions were stable, but T cells showed upregulated antigen receptor signaling. Endothelial cells showed dysregulation in fatty acid transport, but metformin had minimal impact here.

D. Cell-Cell Communication

• Reprogramming: PCOS muscle exhibited enhanced communication between FAPs (senders) and Muscle Fibers (receivers) via Collagen, Laminin, and EGF signaling.
• Key Pathways: Upregulated LAMA2-DAG1 and LAMA2-ITGA7:ITGB1 signaling indicated a stiffening ECM environment.
• Metformin: Partially restored interaction strengths, reducing excessive signaling from FAPs to muscle fibers, suggesting a break in the pro-fibrotic feedback loop.

E. Clinical Correlations

• Hyperinsulinemia & Hyperandrogenism: Strong correlations were found between systemic clinical traits (e.g., AUC Insulin, FAI, SHBG) and transcriptional signatures in FAPs (specifically ROBO2, ELN, SLC8A1) and muscle fibers. This links the systemic endocrine imbalance directly to local tissue remodeling.
• GWAS: Genetic risk loci for PCOS, T2D, and BMI were enriched in specific muscle fiber types (MF-IIx, MF-IIa) and pericytes.

F. In Vitro Validation

• Metabolic Memory: PCOS-derived myotubes retained impaired mitochondrial respiration (lower OCR) in vitro, confirming intrinsic metabolic memory.
• Glucose Sensitivity: Despite mitochondrial defects, PCOS myotubes showed normal glucose uptake in vitro, suggesting that the in vivo insulin resistance is driven by the systemic milieu (hormones) and stromal crosstalk rather than an intrinsic defect in the myotube's glucose transporter machinery.
• Metformin: Did not improve mitochondrial function in in vitro myotubes, reinforcing the finding that metformin's primary benefit in PCOS muscle may be stromal (FAP) rather than myocellular.

5. Significance

• Mechanistic Insight: The study redefines PCOS skeletal muscle pathology as a stromal-driven disease where FAPs act as central hubs, translating systemic hyperinsulinemia and hyperandrogenism into local fibrosis and metabolic inflexibility.
• Therapeutic Implications: It suggests that current insulin-sensitizing approaches may be insufficient if they do not target the pro-fibrotic FAP compartment. Metformin's efficacy appears to stem from its ability to modulate FAP signaling (TGF-β/ECM) rather than directly fixing myocyte mitochondrial function.
• Precision Medicine: The identification of specific responsive (FAPs) and refractory (myofibers) cell populations provides a framework for developing precision therapeutics that target the specific cellular drivers of metabolic dysfunction in PCOS.
• Resource: The dataset serves as a foundational resource for understanding skeletal muscle heterogeneity in metabolic and reproductive disorders.